These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22315990)

  • 1. Initiating breast cancer by PIK3CA mutation.
    Miller TW
    Breast Cancer Res; 2012 Feb; 14(1):301. PubMed ID: 22315990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
    Dunlap J; Le C; Shukla A; Patterson J; Presnell A; Heinrich MC; Corless CL; Troxell ML
    Breast Cancer Res Treat; 2010 Apr; 120(2):409-18. PubMed ID: 19418217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.
    Cheng H; Liu P; Ohlson C; Xu E; Symonds L; Isabella A; Muller WJ; Lin NU; Krop IE; Roberts TM; Winer EP; Arteaga CL; Zhao JJ
    Oncogene; 2016 Jun; 35(23):2961-70. PubMed ID: 26640141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
    Li H; Zhu R; Wang L; Zhu T; Li Q; Chen Q; Wang H; Zhu H
    Exp Mol Pathol; 2010 Feb; 88(1):150-5. PubMed ID: 19818761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas.
    Myers MB; Banda M; McKim KL; Wang Y; Powell MJ; Parsons BL
    Neoplasia; 2016 Apr; 18(4):253-63. PubMed ID: 27108388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors.
    Meyer DS; Brinkhaus H; Müller U; Müller M; Cardiff RD; Bentires-Alj M
    Cancer Res; 2011 Jul; 71(13):4344-51. PubMed ID: 21482677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.
    Liu P; Cheng H; Santiago S; Raeder M; Zhang F; Isabella A; Yang J; Semaan DJ; Chen C; Fox EA; Gray NS; Monahan J; Schlegel R; Beroukhim R; Mills GB; Zhao JJ
    Nat Med; 2011 Aug; 17(9):1116-20. PubMed ID: 21822287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.
    Arthur LM; Turnbull AK; Renshaw L; Keys J; Thomas JS; Wilson TR; Lackner MR; Sims AH; Dixon JM
    Breast Cancer Res Treat; 2014 Aug; 147(1):211-9. PubMed ID: 25104442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model.
    Maguire SL; Peck B; Wai PT; Campbell J; Barker H; Gulati A; Daley F; Vyse S; Huang P; Lord CJ; Farnie G; Brennan K; Natrajan R
    J Pathol; 2016 Nov; 240(3):315-328. PubMed ID: 27512948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.
    Isakoff SJ; Engelman JA; Irie HY; Luo J; Brachmann SM; Pearline RV; Cantley LC; Brugge JS
    Cancer Res; 2005 Dec; 65(23):10992-1000. PubMed ID: 16322248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
    Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
    Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.
    Ang DC; Warrick AL; Shilling A; Beadling C; Corless CL; Troxell ML
    Mod Pathol; 2014 May; 27(5):740-50. PubMed ID: 24186142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria.
    Harlé A; Lion M; Lozano N; Husson M; Harter V; Genin P; Merlin JL
    Oncol Rep; 2013 Mar; 29(3):1043-52. PubMed ID: 23314198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions.
    Troxell ML; Brunner AL; Neff T; Warrick A; Beadling C; Montgomery K; Zhu S; Corless CL; West RB
    Mod Pathol; 2012 Jul; 25(7):930-7. PubMed ID: 22460814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.
    Cufí S; Corominas-Faja B; Lopez-Bonet E; Bonavia R; Pernas S; López IÁ; Dorca J; Martínez S; López NB; Fernández SD; Cuyàs E; Visa J; Rodríguez-Gallego E; Quirantes-Piné R; Segura-Carretero A; Joven J; Martin-Castillo B; Menendez JA
    Oncotarget; 2013 Sep; 4(9):1484-95. PubMed ID: 23986086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of ligase defective E6-associated protein, E6-AP, results in mammary tumorigenesis.
    Ramamoorthy S; Tufail R; Hokayem JE; Jorda M; Zhao W; Reis Z; Nawaz Z
    Breast Cancer Res Treat; 2012 Feb; 132(1):97-108. PubMed ID: 21553290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiplexed imaging reveals heterogeneity of PI3K/MAPK network signaling in breast lesions of known PIK3CA genotype.
    Jacob T; Gray JW; Troxell M; Vu TQ
    Breast Cancer Res Treat; 2016 Oct; 159(3):575-83. PubMed ID: 27581127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients.
    Karakas B; Colak D; Kaya N; Ghebeh H; Al-Qasem A; Hendrayani F; Toulimat M; Al-Tweigeri T; Park BH; Aboussekhra A
    Cancer Biol Ther; 2013 Oct; 14(10):888-96. PubMed ID: 23982433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
    Dirican E; Kaya Z; Gullu G; Peker I; Ozmen T; Gulluoglu BM; Kaya H; Ozer A; Akkiprik M
    Asian Pac J Cancer Prev; 2014; 15(21):9327-33. PubMed ID: 25422220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.
    Van Keymeulen A; Lee MY; Ousset M; Brohée S; Rorive S; Giraddi RR; Wuidart A; Bouvencourt G; Dubois C; Salmon I; Sotiriou C; Phillips WA; Blanpain C
    Nature; 2015 Sep; 525(7567):119-23. PubMed ID: 26266985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.